ESTRO 2024 - Abstract Book

S1602

Clinical - Lung

ESTRO 2024

Conclusion:

The P4C program has demonstrated feasibility in delivering a tailored prehabilitation program to patients due to undergo radical intent radiotherapy for lung cancer. Meaningful improvements in physiological and functional outcomes were demonstrated.

Keywords: Prehabilitation

References:

[1] Gravier F-E, Smondack P, Prieur G, Medrinal C, Combret Y, Muir J-F, et al. Effects of exercise training in people with non-small cell lung cancer before lung resection: a systematic review and meta-analysis. Thorax 2022;77:486 – 96. https://doi.org/10.1136/thoraxjnl-2021-217242. [2] Bradley P, Merchant Z, Rowlinson-Groves K, Taylor M, Moore J, Evison M. Feasibility and outcomes of a real world regional lung cancer prehabilitation programme in the UK. British Journal of Anaesthesia 2023;130:e47 – 55. https://doi.org/10.1016/j.bja.2022.05.034.

329

Proffered Paper

Radiotherapy to Primary Lesion in Metastatic NSCLC after First Line Systemic Therapy, NCT04776083

Enas A ElkhoulyElkhouly, Reham A Abdelaziz, Ahmed S Fathy, Yostena N Mekhail, Eman A Alhelbawy

Menoufia University, Clinical Oncology Department, Shebin Alkom, Egypt

Purpose/Objective:

This study aimed to assess the benefit from radical irradiation to the primary lesion only in patients of metastatic NSCLC who responding to first line systemic therapy.

Material/Methods:

This randomized, phase II study enrolled patients with stage IV NSCLC, and no progression at 4-6 cycles of platinum based chemotherapy or 3 or more months after front-line anti EGFR TKIs /anti ALK TKIs. Patients were randomly assigned (1:1) to control arm (standard treatment; maintenance therapy or observation) or to investigational arm (consolidative lung radiotherapy arm 45Gy/15 fractions followed by standard treatment). The primary end point was PFS; secondary end points were OS, and toxicity. This study is registered with ClinicalTrials.gov, number NCT04776083.